Last Close
Feb 06  •  02:48PM ET
0.5200
Dollar change
+0.0273
Percentage change
5.54
%
Index- P/E- EPS (ttm)- Insider Own19.88% Shs Outstand13.31M Perf Week-17.84%
Market Cap6.92M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float10.67M Perf Month-50.00%
Enterprise Value6.04M PEG- EPS next Q- Inst Own0.30% Short Float12.58% Perf Quarter-89.05%
Income- P/S- EPS this Y- Inst Trans19.35% Short Ratio0.21 Perf Half Y-94.78%
Sales- P/B0.31 EPS next Y- ROA- Short Interest1.34M Perf YTD-13.33%
Book/sh1.67 P/C38.46 EPS next 5Y- ROE- 52W High15.82 -96.71% Perf Year-87.82%
Cash/sh0.01 P/FCF- EPS past 3/5Y39.50% 10.10% ROIC- 52W Low0.49 7.00% Perf 3Y-99.49%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility12.22% 21.67% Perf 5Y-99.88%
Dividend TTM- EV/Sales- EPS Y/Y TTM48.91% Oper. Margin- ATR (14)0.18 Perf 10Y-99.77%
Dividend Ex-Date- Quick Ratio0.88 Sales Y/Y TTM- Profit Margin- RSI (14)36.22 Recom3.00
Dividend Gr. 3/5Y- - Current Ratio0.88 EPS Q/Q89.03% SMA20-29.59% Beta0.37 Target Price140.00
Payout- Debt/Eq0.00 Sales Q/Q- SMA50-48.10% Rel Volume0.10 Prev Close0.49
Employees- LT Debt/Eq0.00 Earnings- SMA200-90.02% Avg Volume6.44M Price0.52
IPOJan 21, 1999 Option/ShortNo / Yes EPS/Sales Surpr.- - Trades Volume539,738 Change5.54%
Date Action Analyst Rating Change Price Target Change
Jul-18-22Resumed Oppenheimer Outperform $26
Mar-07-22Initiated H.C. Wainwright Buy $32
Sep-21-21Initiated Oppenheimer Outperform $30
Sep-02-21Initiated B. Riley Securities Buy $40
Aug-19-21Initiated Cantor Fitzgerald Overweight $35
Feb-05-26 02:12PM
Jan-30-26 08:30AM
Jan-29-26 10:08AM
09:00AM
Jan-28-26 08:30AM
07:30AM Loading…
07:30AM
Jan-21-26 11:12AM
Jan-20-26 02:00AM
Jan-15-26 04:01PM
Jan-13-26 03:30PM
Jan-12-26 10:22AM
Dec-18-25 07:40AM
Dec-17-25 06:57PM
10:07AM
Dec-16-25 02:17PM
09:00AM Loading…
09:00AM
Dec-15-25 03:28PM
Dec-11-25 02:44PM
Dec-10-25 03:42PM
Dec-09-25 08:22AM
Dec-08-25 01:00PM
Dec-05-25 12:19PM
Dec-04-25 08:30AM
Dec-01-25 08:50AM
Nov-26-25 10:15AM
09:16AM
Nov-25-25 08:00AM
Nov-24-25 07:00AM
Nov-20-25 07:18PM
09:41AM
09:00AM Loading…
Nov-19-25 09:00AM
Nov-17-25 03:04PM
10:31AM
Nov-13-25 08:09AM
Nov-12-25 07:00AM
Nov-11-25 08:34AM
Nov-07-25 07:00AM
Nov-05-25 06:19AM
Nov-04-25 08:37PM
Nov-03-25 01:00PM
08:00AM
08:00AM
Oct-31-25 12:55PM
Oct-29-25 10:46AM
Oct-27-25 08:10AM
08:00AM
Oct-25-25 12:30PM
Oct-24-25 08:05AM
Oct-23-25 04:49AM
Oct-22-25 12:45PM
12:00PM
Oct-20-25 07:00AM
Oct-15-25 08:16AM
Oct-14-25 07:00AM
Oct-13-25 07:26AM
Oct-12-25 09:00PM
Oct-11-25 09:48AM
Oct-10-25 08:02AM
Oct-09-25 08:53AM
Oct-08-25 07:16AM
Oct-07-25 09:39AM
Sep-25-25 02:45PM
Sep-03-25 12:37PM
Jul-25-25 04:15PM
Jun-25-25 07:00AM
Jun-09-25 06:00AM
Apr-28-25 06:00AM
Mar-27-25 04:15PM
Mar-12-25 08:00AM
Feb-12-25 04:15PM
Jan-30-25 04:30PM
Jan-06-25 05:00AM
Dec-17-24 07:00AM
Dec-12-24 04:15PM
Nov-26-24 04:05PM
Aug-27-24 08:00AM
Aug-15-24 07:00AM
Aug-13-24 07:00AM
Aug-12-24 07:30AM
Apr-15-24 07:05AM
Apr-12-24 10:33AM
08:01AM
Mar-26-24 08:01AM
Feb-28-24 05:10PM
Jan-04-24 08:00AM
Nov-28-23 04:01PM
Nov-06-23 08:01AM
Sep-29-23 08:00AM
Sep-20-23 08:00AM
Sep-05-23 08:00AM
Aug-30-23 08:00AM
Jul-31-23 04:05PM
Jun-26-23 08:00AM
Jun-05-23 08:00AM
Jun-01-23 08:00AM
Apr-26-23 05:00PM
Mar-07-23 08:00AM
Mar-01-23 08:00AM
Feb-27-23 04:05PM
Feb-15-23 08:00AM
AlphaTON Capital Corp. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. Its portfolio includes first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. The company was founded by Gregory H. Bailey and James Mellon in 1973 and is headquartered in Road Town, British Virgin Islands.